Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...

Recommendations

Info

Lines of EDTRS BSCVA Change from Baseline Primary Eyes (Dry AMD/Soft Drusen) Drusen) Worse than 20/40 @ Baseline 1.5 1.0 0.5 0.0 -0.5 0.5 -1.0 1.0 -1.5 1.5 -2.0 2.0 RHEO 1.0 Lines Tx PLACEBO Mean Line Change Over Time 2.7 Lines Post-baseline Interval 2.2 Lines 3.0 Line 1.3 1.2 1.1 1.1 -0.1 -1.5 Baseline 3 Month 6 Month 9 Month 12 Month (n=19/9) (n=19/9) (n=19/7) (n=16/8) (n=19/7) Lines of EDTRS BSCVA Change from Baseline Primary Eyes (Dry AMD/Soft p=0.0014 repeated measures -1.1 -1.9 Pulido et al., Trans Am Ophthalmol Soc 2002 (interim analysis
Rheopheresis for AMD Regulatory Status Germany (European Community) Approved by Medical Device Regulations (CE-mark) No regular reimbursement by statutory health insurances Reimbursement by several private health insurances Canada USA Approved by Health Canada medical device regulations No reimbursement Investigational device No FDA approval
Page 1 and 2: 26th Annual Meeting April 27 - 30,
Page 3 and 4: heopheresis Blood Plasmaseparation
Page 5 and 6: Rheopheresis for AMD Mechanism of A
Page 7 and 8: Rheopheresis for Microcirculatory D
Page 9: Rheopheresis for AMD www.rheo.com M
Page 14 and 15: Adverse events/side effects: Advers
Page 16 and 17: heopherese-zentrum.de o heo.com he
Page 18 and 19: oNet Registry Update March 2005 dve
Page 20 and 21: oNet Registry Update March 2005 dve
Page 22 and 23: oNet Registry Update March 2005 Hyp
Page 24 and 25: oNet Registry Update March 2005 Hyp
Page 26 and 27: hange in ETDRS-Lines ETDRS ETDRS-Li
Page 28: RheoNet - Registry Summary RheoNet-

Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...

Create successful ePaper yourself

Delete template?

Save as template?